The subset of patients amenable to exon 51 skipping showed a more severe disease course than those amenable to any exon skipping.Over 3 years of follow-up, eteplirsen-treated patients showed a slower rate of decline in ambulation assessed by 6MWT compared to untreated matched HC.<CopyrightInformation>© 2016 The Authors.